Improved risk assessment by integrating up-regulated GCN 5 with clinicopathological features in low-risk endometrial cancer

Qiulin Ge,Zhihong Ai,Shanyun Wen,Li Ma,Miao Dai,Fei Liu,Xiaolu Zhu,Wenjing Ding,Bingqing,Yang,Yincheng Teng
2017-01-01
Abstract:Objective: To investigate the clinicopathological relevance of GCN5 protein expression in endometrial cancer (EC). Methods: Immunohistochemical (IHC) analysis by Mann-Whitney U test was undertaken on 11 formalin-fixed paraffin-embedded (FFPE) non-tumorous (NT) endometrium tissues and 107 FFPE EC samples collected between 2009 and 2013. The correlations between GCN5 and clinicopathological parameters in EC were analyzed by Fisher’s exact test or Chi-square test. Mann-Whitney U test was exployed for ranked data and Kaplan-Meier curve with Log-rank test for analyzing the asscociations between OS and categorical variables. Results: The GCN5 IHC expression was significantly up-regulated in EC, where 91% (95/104) and 9% (9/104) of patients with clinical data displayed high GCN5 expression and low GCN5 expression, respectively. Histological staining of GCN5 was stronger in endometrioid adenocarcinoma (EEC) than in non-endometrioid EC (NEEC). Moreover, GCN5 expression was inversely related with lymphatic-metastasis. Patients with high-level GCN5, non-lympho-vascular space invasion (N-LVSI) and early-stage lived significantly longer than those with the opposites; within subsets of grade 1, stage I and non-vascular invasion, high-level GCN5 confers better overall survival. Conclusions: High GCN5 IHC expression is positively associated with endometrioid adenocarcinoma, non-lymphatic metastasis and excellent clinical outcome in EC. Integrating clinicopathological factors with GCN5 results in improved risk assessment in low-risk EC patients.
What problem does this paper attempt to address?